Program Overview. Why, When, and How to Switch ART in Patients With HIV Who Have Achieved Viral Suppression.

Slides:

Advertisements

Similar presentations

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

Advertisements

BHIVA Clinical Audit Management of patients who switch therapy; re-audit of patients starting therapy from naïve.

ZIMBABWE AIDS CARE FOUNDATION NEWLANDS CLINIC Virological Outcomes in Adult Patients on Second Line ART, at Newlands Clinic Dr S. Bote.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.

Phase 3 Treatment Experienced

Treatment-Naïve Adults

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Phase 3 Treatment-Naïve and Treatment-Experienced

Virological and immunological efficacy of regimen including MVC

Switch from TDF-based to Elvitegravir-Cobicistat-TAF-FTC Study 109

Updated DHHS Adult and Adolescent HIV Treatment Guidelines: Conversation with Dr. Paul Sax Presentation prepared by: Paul Sax, MD and Brian Wood, MD.

Phase 3 Treatment-Naïve and Treatment-Experienced

The Nurse View: Management of Pancreatic Cancer

Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5

Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Back to School 2013: An Immunization Checklist

RISK RECOGNITION IN HEALTHCARE SETTINGS

The Nurse View Key Insights Along the CML Continuum

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Initiatives in HIV.

Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

HIV Management: An Update on the Latest EACS Guidelines

Is Your Patient Engaged in Care

T-Cell Directed Therapy in MS

Understanding Statin Metabolism

What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?

Obesity Management Today:

Translating Emerging HIV Data Into Clinical Practice

Tailoring Hemophilia Prophylaxis Therapy

Evaluation of the Patient With HCV Infection

Clinical Updates in RA: New Developments and Insights From Washington

Statins, HIV, and CVD.

Seizures in the Elderly: Treatment and Special Considerations

CoreValve US Pivotal Trial High-Risk Arm Device and Access Routes.

HIV : New Agents, New Strategies

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Poor Response to Initial Therapy for Migraine

HIV Treatment: What Can You Do to Get and Keep Patients in Care?

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

Why Dolutegravir? Daniel R. Kuritzkes, M.D.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Statins, HIV, and CVD.

Better Diabetes Control With Novel Basal Insulins

Reexamining the Basics of HFpEF

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Insulin in Diabetes Management: Effective Patient Selection Is Key

Critical Decision Points in Insomnia

HIV Update 2018: A Front Row Seat

Add-On Therapy to Insulin in T1DM Management

Proteasome Inhibitors and Patients

ART Options and Treatment Decisions for Women of Reproductive Potential

Program Goal. Program Goal Disclaimer Overview.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Checkpoint Inhibitors in First-Line Advanced NSCLC

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products?

Real-World Evidence.

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Background. Long-Term B/F/TAF Switch Efficacy in Patients with Archived Pre-Existing Resistance.

Phase 3 Treatment-Naïve and Treatment-Experienced

Fixed-Ratio Combination Therapy in T2DM

Tertiary structures of viral integrase and chemical formulas of HIV integrase inhibitors. Tertiary structures of viral integrase and chemical formulas.

Characterizing Virological Suppression in Today's Treatment Paradigm

Best Practices in Building HIV Care Networks

Presentation transcript:

Why, When, and How to Switch ART in Patients With HIV Who Have Achieved Viral Suppression

Program Overview

Reasons to consider switching in virologically suppressed Patients with HIV

Reasons for Switching in Virologically Suppressed Patients

Switching Categories in Virologically Suppressed Patients

Reasons for Switching in Asymptomatic Patients

Further Reasons for Switching

Don’t Fix It If It Ain’t Broken… Except To…

Issues to Consider Before Switching

Considerations After Decision to Switch

Considerations After Decision to Switch (cont)

A Menu of Switches….

ARDENT Trial

Reasons for Switching Determine Therapeutic Choice

Coinfected Patients

Ongoing Dolutegravir Switch Studies

Ongoing Raltegravir Switch Studies

Ongoing Elvitegravir Switch Studies

New Switching Data at IAS, Vancouver

New Switching Data at ICAAC, San Diego

Upon Deciding to Switch: What Are the Key Considerations?

Regional Considerations

Conclusions

Abbreviations

Abbreviations (cont)

References